I’m Justin Danhof of the National Center for Public Policy Research.

Mr. Ricks, millions of Americans are struggling under the market-distorting mechanisms of the Affordable Care Act. Eli Lilly played a major role in that suffering through its integral role in the implementation, promotion and defense of ObamaCare. As you know, PhRMA spent more than $100 million on advertisements to promote ObamaCare.

Now that there is an actual opportunity to repeal and replace ObamaCare with a more market-oriented health care delivery system, it is incumbent upon corporations responsible for ObamaCare’s creation to be part of its solution.

In contrast to some other leaders in the pharmaceutical industry, you have portrayed a positive image of President Trump’s health care reform efforts. After meeting with the President, you noted “a number of his policy proposals which, on balance, I think would be very good for us. Looking at regulatory reform at the FDA, the changes that are being contemplated on repealing and replacing the Affordable Care Act, and taxation… All those things were good.”

As the current political climate offers a unique opportunity for both private industry and health care consumers, I have a few quick questions: What message do you have for the millions of Americans who have seen their health care choices diminish, premiums rise, deductibles go through the roof, or well-being otherwise harmed by ObamaCare? Will you commit to work with the Trump Administration on health care reform? And what specific reforms would you suggest to the new President?

Contact: Judy Kent at (703) 759-7476 or cell (703) 477-7476 or jkent@nationalcenter.org
National Center for Public Policy Research
20 F Street, NW, Suite 700
Washington, DC 20001

www.nationalcenter.org • www.conservativeblog.org • @NationalCenter

http://www.indystar.com/story/money/2017/01/31/lilly-ceo-joins-pharmaceutical-chiefs-meeting-trump/97275982/